Key result
Adipose stromal cells from smokers completely lose therapeutic efficacy for ischemic limb perfusion versus nonsmokers.
Why the study?
The effect of cigarette smoking on the ability of adipose stem/stromal cells to promote vasculogenesis and rescue perfusion in ischemia was unknown.
Does cigarette smoking impair the vasculogenic activity and therapeutic potential of adipose stromal cells in ischemia?
Does cigarette smoking impair the vasculogenic activity and therapeutic potential of adipose stromal cells in ischemia?
Cigarette smoking impairs the therapeutic vasculogenic activity of adipose stromal cells in ischemia by altering their secretome, specifically increasing the angiostatic factor Activin A.
ASC from smokers lose vasculogenic efficacy in ischemia models; leaves open donor screening needs and human translation.
Cigarette smoking (CS) adversely affects the physiologic function of endothelial progenitor, hematopoietic stem and progenitor cells. However, the effect of CS on the ability of adipose stem/stromal cells (ASC) to promote vasculogenesis and rescue perfusion in the context of ischemia is unknown. To evaluate this, ASC from nonsmokers (nCS-ASC) and smokers (CS-ASC), and their activity to promote perfusion in hindlimb ischemia models, as well as endothelial cell (EC) survival and vascular morphogenesis in vitro were assessed. While nCS-ASC improved perfusion in ischemic limbs, CS-ASC completely lost this therapeutic effect. In vitro vasculogenesis assays revealed that human CS-ASC and ASC from CS-exposed mice showed compromised support of EC morphogenesis into vascular tubes, and the CS-ASC secretome was less potent in supporting EC survival/proliferation. Comparative secretome analysis revealed that CS-ASC produced lower amounts of hepatocyte growth factor (HGF) and stromal cell-derived growth factor 1 (SDF-1). Conversely, CS-ASC secreted the angiostatic/pro-inflammatory factor Activin A, which was not detected in nCS-ASC conditioned media (CM). Furthermore, higher Activin A levels were measured in EC/CS-ASC cocultures than in EC/nCS-ASC cocultures. CS-ASC also responded to inflammatory cytokines with 5.2-fold increase in Activin A secretion, whereas nCS-ASC showed minimal Activin A induction. Supplementation of EC/CS-ASC cocultures with nCS-ASC CM or with recombinant vascular endothelial growth factor, HGF, or SDF-1 did not rescue vasculogenesis, whereas inhibition of Activin A expression or activity improved network formation up to the level found in EC/nCS-ASC cocultures. In conclusion, ASC of CS individuals manifest compromised in vitro vasculogenic activity as well as in vivo therapeutic activity. Stem Cells 2018;36:856-867.
No takes yet. Share an insight, caveat, or question.
Barwinska et al. (2018) studied Ischemia. Cigarette smoking vs. Nonsmokers was evaluated on Vasculogenic activity and perfusion in ischemic limbs. Adipose stromal cells from smokers completely lost their therapeutic effect to improve perfusion in ischemic limbs and showed compromised in vitro vasculogenic activity compared to nonsmokers.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: